Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer.

In TROP2-high PEO1-olaJR models, SG showed a trend toward lower disease burden, but it did not differ from the combination ( Figure S7 C).

also in 53,322 other papers